Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective […]
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average […]
Cantor Fitzgerald reiterated their neutral rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a research report report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2023 earnings at ($1.57) EPS and FY2024 earnings at ($0.99) EPS. A number of other research firms have also recently weighed […]
Archbishop Monahan archregina.sk.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from archregina.sk.ca Daily Mail and Mail on Sunday newspapers.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) insider Joseph Monahan sold 6,000 shares of the stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $5.08, for a total value of $30,480.00. Following the completion of the transaction, the insider now directly owns 129,724 shares in the […]